P/E ratio for Astellas Pharma (4503.T)
P/E ratio as of March 2023 (TTM): 16.6
According to Astellas Pharma's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 16.6014. At the end of 2022 the company had a P/E ratio of 29.1.
P/E ratio history for Astellas Pharma from 2009 to 2022
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 29.1 | 9.21% |
| 2021 | 26.7 | 61.29% |
| 2020 | 16.5 | 12.42% |
| 2019 | 14.7 | -26.09% |
| 2018 | 19.9 | 38.71% |
| 2017 | 14.3 | -14.54% |
| 2016 | 16.8 | -48.07% |
| 2015 | 32.3 | -13.62% |
| 2014 | 37.4 | 37.36% |
| 2013 | 27.2 | 35.73% |
| 2012 | 20.1 | -4.53% |
| 2011 | 21.0 | 63.36% |
| 2010 | 12.9 | 45.04% |
| 2009 | 8.87 | -21.8% |
| 2008 | 11.3 | -48% |
| 2007 | 21.8 | -12.42% |
| 2006 | 24.9 | -36.24% |
| 2005 | 39.1 | 29.99% |
| 2004 | 30.1 |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.